definiens: , and shall be construed accordingly . means : ( A ) for ( i ) Purchased Clinical API and ( ii ) Maintained Excess Clinical API subsequently purchased by the Purchaser pursuant to Clause 2.2, FCA ( current locatio n of Purchased Clinical API or Maintained Excess Clinical API, as applicable ) ( Incoterms 2010 ), except for Purchased Clinical API or Maintained Excess Clinical API that the Parties agree will be left in [COMPANY] ’s possession on consignment pursuant to Clause 10 ( Delivery of Product ) ; provided that [COMPANY] will be responsible for the transportation of Purchased Clinical API ( or Maintained Excess Clinical API subsequently purchased by the Purchaser pursuant to Clause 2.2 ) to Barnard Castle as required ( and transportation costs and any Taxes associated th erewith ( to the extent not separately reimbursed by the Purchaser ) will be part of the LAV for the Manufacture of New Clinical Products ) ; ( B ) for Existing Clinical Product and Existing Clinical Placebo, FCA ( current location of Existing Clinical Product or Existing Clinical Placebo ) ( Incoterms 2010 ) ; ( C ) for New Clinical API, FCA ( Cork, Ireland ) ( Incoterms 2010 ), except for New Clinical AP I that the Parties agree will be left in [COMPANY] ’s possession on consignment pursuant to Clause 10 ( Delivery of Product ) ; provided that [COMPANY] will be responsible for the transportation of New Clinical API to Barnard Castle as required ( and transportation costs a nd any Taxes associated therewith ( to the extent not separately reimbursed by the Purchaser ) will be part of the LAV for the Manufacture of New Clinical Products ) ; and CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [ * * * ], HAS BEEN OMITTED BECAUSE DERMAVANT SCIENCES LTD . HAS DETERMINED THE INFORMATION ( I ) IS NOT MATERIAL AND ( II ) WOULD LIKELY CAUSE COMPETITIVE HARM TO DERMAVANT SCIENCES LTD . IF PUBLICLY DISCLOSED